English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/188101
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:

Title

Clinical implications of the deregulated TP73 isoforms expression in cancer

AuthorsRodríguez, Nuria ; Peláez, A.; Barderas, Rodrigo ; Domínguez, Gemma
KeywordsClinical translation
Cancer
Human patients
Prognosis
TP73 isoforms
Issue Date2018
PublisherSpringer Nature
CitationClinical and Translational Oncology 20(7): 827-836 (2018)
AbstractTP73 is a member of the TP53 family whose expression has been observed altered in most human cancers and associated with the prognosis. TP73 translates into a complex number of isoforms with both oncogenic and tumour-suppressor functions and presents a complex cross-talk with other members of the family (TP53 and TP63). In this revision, we focus on the evidence that may support TP73 variants as prognostic markers in cancer. Nowadays, most publications in this topic highlight the association between overexpression of the oncogenic variants and failure to respond to chemotherapy and/or shorter survival. In addition, we comment on the putative possibilities that the detection through a liquid biopsy of TP73 variants may provide, and finally, the significance of determining the value of the combined alteration of the TP53 family members in the clinical setting.
Publisher version (URL)https://doi.org/10.1007/s12094-017-1802-3
URIhttp://hdl.handle.net/10261/188101
DOI10.1007/s12094-017-1802-3
ISSN1699-048X
E-ISSN1699-3055
Appears in Collections:(IIBM) Artículos
Files in This Item:
File Description SizeFormat 
accesoRestringido.pdf59,24 kBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 

Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.